October 12, 2026 12:36 pm
Key Moments Adobe stock declined 2.6% in pre-market trading to $236.03 following a double-downgrade by Wells Fargo analyst Michael Turrin. The analyst cut his rating from Overweight to Underweight and reduced his price target from $270 to $225, citing AI budget shifts and subscription growth concerns. The move added to pressure already sparked by Adobe’s […]
Read moreOctober 12, 2026 12:34 pm
Key Moments Western Digital Corporation (WDC) declined 31.81% over the past three months, with the chart still showing technical damage despite solid business momentum. Consensus for the September quarter calls for $4.14B in revenue and EPS of $4.07, ahead of the scheduled October 22, 2026 after-hours earnings release. FinQL’s Fair Value model indicated 27.2% upside […]
Read moreOctober 12, 2026 12:24 pm
Key Moments The NVIDIA tokenized stock contract on Binance Futures traded at $229.90 during the October 12 observation, down $0.97 or 0.42%, with a notably narrow 24-hour range versus its 14-period ATR of $4.11. Price has slipped below the SMA 7, SMA 20, and EMA 12, while the MACD histogram sits at 0.0000 as the […]
Read moreOctober 12, 2026 12:22 pm
Key Moments Micron Technology Inc (MU) trades at $1,005.58 in premarket, down 2.28% from the prior close of $1,029.00 as of October 12, 2026 at 8:11 AM EDT. Technical indicators show a strong weekly uptrend alongside oversold daily readings, pointing to short-term weakness within a longer-term advance. Recent quarterly results surpassed EPS and revenue estimates, […]
Read moreOctober 12, 2026 12:17 pm
Key Moments Bristol-Myers Squibb (NYSE:BMY) climbed 5.7% in pre-market trading, with shares touching $62.50 following two positive Phase 3 trial readouts released the same morning. RYZ101 in the ACTION-1 trial and admilparant in the ALOFT-IPF study each met their primary endpoints, with BMS indicating plans to pursue FDA engagement for RYZ101. The stock move occurred […]
Read moreOctober 12, 2026 12:15 pm
Key Moments JPMorgan raised its rating on Biogen to Overweight from Neutral and set a December 2027 price target of $300 per share. Analyst Chris Schott highlighted three key clinical readouts by 2027, led by felzartamab in antibody-mediated rejection, targeting a market over $2 billion. Schott anticipates Biogen’s EPS growth to accelerate from mid single […]
Read moreOctober 12, 2026 11:16 am
Key Moments Broadcom Inc. CEO Hock Tan compared parts of the AI investment boom to gambling, saying many investors set extreme expectations without understanding large language models. Tan highlighted that OpenAI reached annualized revenue of $50 billion in September, yet is still losing money because of high model training costs. Industry leaders on the same […]
Read moreOctober 9, 2026 2:09 pm
Key Moments NVIDIA’s ACIE segment, which includes neoclouds, grew 138% year-on-year to $40.3B in Q2 FY27, underscoring robust underlying demand. CoreWeave (CRWV) was previously flagged with a debt-to-equity ratio of 738.5% and free cash flow of -$10.62B, highlighting significant leverage risk. Nebius (NBIS) has gained 152.6% year-to-date and rose roughly 32% after its August 12 […]
Read moreOctober 9, 2026 2:02 pm
Key Moments A jury is set to decide whether Arm breached licensing agreements with Qualcomm and interfered with Qualcomm’s relationship with Meta Platforms. The dispute centers on Arm’s alleged withholding of software tools and patches, as well as pricing protections and a leaked breach notice. A separate bench trial on whether Arm is negotiating new […]
Read moreOctober 9, 2026 1:58 pm
Key Moments Netflix is reportedly planning to cut about 5% of its workforce, with an announcement expected as early as next week, according to Puck News. The company had about 16,000 full-time employees at the end of last year, providing context for the potential scale of the cuts. Netflix is expanding into advertising, live programming […]
Read more